• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy
    Subscribe to $BKHA

    Black Hawk Acquisition Corporation

    Subscribe to $BKHA
    $BKHA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    IPO Year: 2024

    Exchange: NASDAQ

    Recent Analyst Ratings for Black Hawk Acquisition Corporation

    DatePrice TargetRatingAnalyst
    See more ratings

    Black Hawk Acquisition Corporation Press Releases

    Fastest customizable press release news feed in the world

    View All

    Vesicor Therapeutics Appoints Michael Tolentino, M.D., as Chief Executive Officer

    BLACKHAWK, Calif., March 18, 2026 (GLOBE NEWSWIRE) -- Vesicor Therapeutics, Inc., a San Gabriel, California-based early development stage biotechnology corporation focused on the development of p53-based cancer therapeutics delivered via precision-engineered microvesicles and a proposed de-SPAC acquisition target for Black Hawk Acquisition Corporation (NASDAQ:BKHA, BKHAU, BKHAR)), today announced that its Board of Directors has appointed Michael Tolentino, M.D., an accomplished biotech leader with deep industry experience, as Chief Executive Officer (CEO), effective March 17, 2026. He succeeds Founder and CEO Luo Feng, Ph.D., who has been appointed Chief Scientific Officer. "Dr. Tolentino

    3/18/26 10:42:50 PM ET
    $BKHA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Black Hawk Acquisition Corporation Leadership Updates

    Live Leadership Updates

    View All

    Vesicor Therapeutics Appoints Michael Tolentino, M.D., as Chief Executive Officer

    BLACKHAWK, Calif., March 18, 2026 (GLOBE NEWSWIRE) -- Vesicor Therapeutics, Inc., a San Gabriel, California-based early development stage biotechnology corporation focused on the development of p53-based cancer therapeutics delivered via precision-engineered microvesicles and a proposed de-SPAC acquisition target for Black Hawk Acquisition Corporation (NASDAQ:BKHA, BKHAU, BKHAR)), today announced that its Board of Directors has appointed Michael Tolentino, M.D., an accomplished biotech leader with deep industry experience, as Chief Executive Officer (CEO), effective March 17, 2026. He succeeds Founder and CEO Luo Feng, Ph.D., who has been appointed Chief Scientific Officer. "Dr. Tolentino

    3/18/26 10:42:50 PM ET
    $BKHA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Black Hawk Acquisition Corporation Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Black Hawk Acquisition Corporation

    SC 13G/A - Black Hawk Acquisition Corp (0002000775) (Subject)

    11/15/24 9:17:26 AM ET
    $BKHA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G filed by Black Hawk Acquisition Corporation

    SC 13G - Black Hawk Acquisition Corp (0002000775) (Subject)

    11/14/24 8:39:26 PM ET
    $BKHA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G filed by Black Hawk Acquisition Corporation

    SC 13G - Black Hawk Acquisition Corp (0002000775) (Subject)

    11/14/24 6:13:30 PM ET
    $BKHA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G filed by Black Hawk Acquisition Corporation

    SC 13G - Black Hawk Acquisition Corp (0002000775) (Subject)

    11/14/24 9:58:25 AM ET
    $BKHA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Black Hawk Acquisition Corporation

    SC 13G/A - Black Hawk Acquisition Corp (0002000775) (Subject)

    11/12/24 4:27:55 PM ET
    $BKHA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G filed by Black Hawk Acquisition Corporation

    SC 13G - Black Hawk Acquisition Corp (0002000775) (Subject)

    11/12/24 9:33:06 AM ET
    $BKHA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G filed by Black Hawk Acquisition Corporation

    SC 13G - Black Hawk Acquisition Corp (0002000775) (Subject)

    6/7/24 4:02:35 PM ET
    $BKHA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Black Hawk Acquisition Corporation SEC Filings

    View All

    SEC Form 10-Q filed by Black Hawk Acquisition Corporation

    10-Q - Black Hawk Acquisition Corp (0002000775) (Filer)

    4/20/26 6:23:25 PM ET
    $BKHA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form NT 10-Q filed by Black Hawk Acquisition Corporation

    NT 10-Q - Black Hawk Acquisition Corp (0002000775) (Filer)

    4/14/26 4:14:17 PM ET
    $BKHA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Black Hawk Acquisition Corporation filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

    8-K - Black Hawk Acquisition Corp (0002000775) (Filer)

    4/1/26 4:56:37 PM ET
    $BKHA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Black Hawk Acquisition Corporation filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Black Hawk Acquisition Corp (0002000775) (Filer)

    3/17/26 5:30:00 PM ET
    $BKHA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 10-K filed by Black Hawk Acquisition Corporation

    10-K - Black Hawk Acquisition Corp (0002000775) (Filer)

    3/6/26 5:12:45 PM ET
    $BKHA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form NT 10-K filed by Black Hawk Acquisition Corporation

    NT 10-K - Black Hawk Acquisition Corp (0002000775) (Filer)

    3/2/26 4:05:07 PM ET
    $BKHA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Black Hawk Acquisition Corporation filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Unregistered Sales of Equity Securities, Financial Statements and Exhibits

    8-K - Black Hawk Acquisition Corp (0002000775) (Filer)

    2/19/26 3:13:51 PM ET
    $BKHA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Black Hawk Acquisition Corporation filed SEC Form 8-K: Leadership Update

    8-K - Black Hawk Acquisition Corp (0002000775) (Filer)

    2/3/26 1:07:08 PM ET
    $BKHA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form S-4/A filed by Black Hawk Acquisition Corporation

    S-4/A - Black Hawk Acquisition Corp (0002000775) (Filer)

    1/22/26 9:44:40 PM ET
    $BKHA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form DEL AM filed by Black Hawk Acquisition Corporation

    DEL AM - Black Hawk Acquisition Corp (0002000775) (Filer)

    12/29/25 2:51:31 PM ET
    $BKHA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care